Recent Updates
Recently added Catalysts
ALNY Positive Sentiment

Resumen: Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por trans...

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Alnylam Pharmaceuticals presented new data at the 2026 ESC Congress, demonstrating the effectiveness of RNA interference in silencing transthyretin. This research focuses on patient populations and treatment settings for transthyretin amyloid cardiomyopathy. The findings support Alnylam's position as a leader in RNA interference therapies.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data reinforces efficacy of transthyretin silencing.
  • Presentation at a major cardiology congress highlights advancements.
  • Alnylam continues to lead in RNA interference therapies.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
1.9%
average across 8 past catalysts
Lead asset
ALN-4324
Phase 1 · Obese or Overweight Healthy Volunteers

Full Press Release Details

CAMBRIDGE, Massachusetts--(BUSINESS WIRE)--  Alnylam presenta nuevos datos en el Congreso 2026 de la ESC que refuerzan la eficacia en el silenciamiento de la transtiretina mediante interferencia de ARN en poblaciones de pacientes y entornos de tratamiento de miocardiopatía amiloide por transtiretina Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), la empresa líder en terapias de interferencia de ARN, anunció nuevos datos en el Congreso 2026 de la Sociedad Europea de Cardiología (ESC) que demuestra

Frequently Asked Questions

What new data did Alnylam present at ESC 2026?

Alnylam presented data demonstrating the efficacy of RNA interference in silencing transthyretin.

What is the focus of Alnylam's research?

The research focuses on patient populations and treatment settings for transthyretin amyloid cardiomyopathy.

What is Alnylam's position in RNA therapies?

Alnylam is recognized as a leader in RNA interference therapies.

ShareAdd on Google
Tags: ALNY Viatris Investor Conferences Healthcare Alnylam RNA interference transthyretin ESC 2026 amyloid cardiomyopathy
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$3308M liquidity · $0M/mo burn
Low dilution risk
Lead asset
ALN-4324Phase 1
Obese or Overweight Healthy Volunteers →

Catalyst track record

+25%
best trade around ALNY's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ALNY.

See every catalyst's timing & PoA →